Immunotherapy, genetic testing could offer cancer patients a breakthrough treatment

Immunotherapy continues to be an interesting prospect for research and development across all types of medicine. A recent feature in the Washington Post takes a deep dive into one example of the potential benefits.

Stefanie Joho, at just 23 years old, was suffering from colon cancer when she discovered a cancer geneticist's clinical trial at Johns Hopkins University. The breakthrough could benefit some patients with certain kinds of advanced cancer that aren’t responding to chemotherapy. Each should be tested for that genetic signature, scientists stress.

“These are people facing death sentences,” said Hopkins geneticist Bert Vogelstein. “This treatment might keep some of them in remission for a long time.”

To read the full story, click here:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”